QIAGEN (QGEN) Announces CE Mark on Next Generation Molecular Diagnostic for KRAS Analysis

June 2, 2009 1:30 PM EDT

QIAGEN (NASDAQ: QGEN) announced the official launch of its next-generation CE-labelled assay for KRAS testing in colorectal cancer patients. In addition, the company gave an update on the pipeline of its regulated assay portfolio for personalized cancer treatment based upon the Pyrosequencing technology. As evidenced by the significant expansion of its portfolio in this area, the company intends to provide its customers a broad portfolio of fully CE-marked sample-to-result technologies for tumor mutation profiling for various cancers. QIAGEN believes that these solutions will provide significant value to oncology diagnostics and to research.

QIAGEN N.V. (QIAGEN) is a provider of technologies and products for preanalytical sample preparation and linked molecular assay solutions.[SM]

Create E-mail AlertRelated Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?